Is Continuous Eruption Related to Periodontal Changes? A 16-Year Follow-up.

J Dent Res

Department of Restorative Dentistry, Periodontology, Endodontology, Preventive Dentistry and Pedodontics, University Medicine Greifswald, Greifswald, Germany.

Published: July 2021

The aims of this study were to 1) determine if continuous eruption occurs in the maxillary teeth, 2) assess the magnitude of the continuous eruption, and 3) evaluate the effects of continuous eruption on the different periodontal parameters by using data from the population-based cohort of the Study of Health in Pomerania (SHIP). The jaw casts of 140 participants from the baseline (SHIP-0) and 16-y follow-up (SHIP-3) were digitized as 3-dimensional models. Robust reference points were set to match the tooth eruption stage at SHIP-0 and SHIP-3. Reference points were set on the occlusal surface of the contralateral premolar and molar teeth, the palatal fossa of an incisor, and the rugae of the hard palate. Reference points were combined to represent 3 virtual occlusal planes. Continuous eruption was measured as the mean height difference between the 3 planes and rugae fix points at SHIP-0 and SHIP-3. Probing depth, clinical attachment levels, gingiva above the cementoenamel junction (gingival height), and number of missing teeth were clinically assessed in the maxilla. Changes in periodontal variables were regressed onto changes in continuous eruption after adjustment for age, sex, number of filled teeth, and education or tooth wear. Continuous tooth eruption >1 mm over the 16 y was found in 4 of 140 adults and averaged to 0.33 mm, equaling 0.021 mm/y. In the total sample, an increase in continuous eruption was significantly associated with decreases in mean gingival height ( = -0.34; 95% CI, -0.65 to -0.03). In a subsample of participants without tooth loss, continuous eruption was negatively associated with PD. This study confirmed that continuous eruption is clearly detectable and may contribute to lower gingival heights in the maxilla.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258728PMC
http://dx.doi.org/10.1177/0022034521999363DOI Listing

Publication Analysis

Top Keywords

continuous eruption
36
reference points
12
continuous
10
eruption
10
eruption periodontal
8
points set
8
tooth eruption
8
ship-0 ship-3
8
gingival height
8
periodontal changes?
4

Similar Publications

We report a case of kerion celsi caused by in a teenage male judo athlete, presenting with a lesion in the occipital region. Following the initiation of systemic antifungal therapy, the patient developed a dermatophytid reaction, necessitating differentiation from a drug eruption. Direct microscopy of the affected area confirmed the presence of fungal elements, and histopathological examination revealed endothrix invasion, supporting the continuation of treatment.

View Article and Find Full Text PDF

Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab.

View Article and Find Full Text PDF

Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review.

Arch Dermatol Res

January 2025

Department of Dermatology, College of Medicine, The Ohio State University Wexner Medical Center, 540 Officenter Place, Columbus, OH, 43230, USA.

The use of immunotherapy is an emerging treatment option for advanced malignancies. Cutaneous adverse events following cancer immunotherapy are well-documented in the literature. The rarer cutaneous adverse effects are less characterized, including eruptive keratoacanthomas (KA).

View Article and Find Full Text PDF

Erlotinib-induced Perioral Lesions Resembling Scleroderma.

Acta Dermatovenerol Croat

November 2024

Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.

View Article and Find Full Text PDF

Phototoxic reaction to oral terbinafine due to Tinea capitis in a child.

Acta Dermatovenerol Croat

November 2024

Prof. Ana Bakija-Konsuo, MD, PhD, Clinic for Dermatovenerology CUTIS, Vukovarska 22, Dubrovnik, Croatia;

We report the case of an 18-month-old boy who developed a phototoxic skin reaction to terbinafine on his scalp, ears, and face in the form of disseminated erythematous plaques, which resembled subacute lupus erythematosus (SCLE) in their clinical presentation. Skin changes appeared a short time after the boy was exposed to sunlight during the period of time when he was treated with oral terbinafine due to Microsporum canis fungal scalp infection. Tinea capitis is a common dermatophyte infection primarily affecting prepubertal children (1).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!